- Home
- RARE vs NVG Comparison
RARE vs NVG Comparison
Compare RARE & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | NVG |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | NVG |
|---|---|---|
| Price | $22.74 | $12.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $73.11 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 568.8K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $630,598,000.00 | N/A |
| Revenue This Year | $19.68 | N/A |
| Revenue Next Year | $19.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | N/A |
| 52 Week Low | $18.41 | $9.68 |
| 52 Week High | $46.50 | $12.21 |
Technical Indicators
Market Signals| Indicator | RARE | NVG |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 60.63 |
| Support Level | $22.40 | $12.55 |
| Resistance Level | $24.65 | $12.93 |
| Average True Range (ATR) | 1.53 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 64.17 | 77.66 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.